Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Imbruvica

EU flag

Orphan drugs in latest CHMP recommendations

EMA advisers back new products from Genzyme, Boehringer and others

- PMLiVE

EMA recommends two AbbVie treatments for hepatitis C

Exviera and Viekirax backed for use in Europe

EU flag

EU watchdog raps EMA for redacted AbbVie data

Issues over the redaction of clinical study reports

- PMLiVE

AbbVie takes home company of the year at PMEA 2014

Firm is rewarded for its patient-focus

- PMLiVE

AZ advances immuno-oncology ambitions

Buys imaging company and signs PD-1 collaborations with Pharmacyclics and J&J

- PMLiVE

AbbVie is not looking at another big acquisition, says CEO

Unlikely to consider another deal on the scale of failed Shire merger

- PMLiVE

AbbVie and Shire bring merger plans to a close

Blames tax changes in the US

- PMLiVE

Janssen’s blood cancer drug Imbruvica approved in Europe

European commission licenses the first-in-class drug for two rare diseases

- PMLiVE

AbbVie teams up with charities to raise awareness of bronchiolitis

Most common cause of infant hospital admissions in winter

- PMLiVE

AbbVie board recommends dropping Shire deal

Tells stakeholders to vote against merger in light of new rules on corporate tax

- PMLiVE

AbbVie rethinks Shire merger in light of US tax crackdown

Follows action to discourage 'inversion deals' aimed at reducing corporate tax rates

- PMLiVE

BMS and Janssen to assess PD1 cancer combination

Will test Opdivo and Imbruvica in non-Hodgkin lymphoma

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links